Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Venetoclax and Obinutuzumab in CLL

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

July 30th 2020

Second-Generation BTK Inhibitors in CLL

July 30th 2020

Therapies in the Pipeline for Frontline CLL

July 30th 2020

Telemedicine for Patients With CLL

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

EU Panel Recommends Ibrutinib/Rituximab Combo for Frontline CLL

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Al-Sawaf on Continual MRD Assessment ​After Venetoclax/Obinutuzumab in CLL

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Dr. Davids on the Design of the Phase 3 UNITY Trials in Relapsed/Refractory CLL and MCL

July 17th 2020

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.